RESUMO
BACKGROUND: The development of chimeric antigen receptor (CAR) Tcells has shown promising results in relapsed/refractory Bcell acute lymphoblastic leukemia/lymphoma (B-ALL) and diffuse large cell Bcell lymphoma. Complications, especially cytokine release syndrome (CRS) and CAR Tcell related encephalopathy syndrome (CRES), can be life threatening. The management of both plays a key role in CAR Tcell therapy. OBJECTIVES: Diagnosis, clinical presentation and development of complications in the treatment with CAR Tcells. MATERIALS AND METHODS: Summary of incidence, mortality and treatment of severe complications after administration of CAR Tcells referring to current studies and therapy recommendations. RESULTS: Complications after administration of CAR Tcells, especially CRS and CRES, can be life threatening. The timely identification of side effects and their appropriate treatment usually leads to complete recovery. CONCLUSIONS: Using a therapy algorithm in the treatment with CAR Tcells allows safe management of toxicities and can be helpful in recognizing them in time.
Assuntos
Leucemia-Linfoma Linfoblástico de Células Precursoras/terapia , Receptores de Antígenos Quiméricos , Síndrome da Liberação de Citocina , Citocinas , Humanos , Imunoterapia AdotivaRESUMO
BACKGROUND: Due to the use of checkpoint inhibitors, intensive care units will be confronted with an increasing number of patients with immune-related adverse events. A broad spectrum of symptoms and potentially lethal consequences make diagnosis and treatment challenging. OBJECTIVES: Diagnosis and treatment of immune-related adverse events in the treatment with checkpoint inhibitors with a special focus on intensive care units. MATERIALS AND METHODS: Review of current publications about incidence, symptoms and treatment of adverse events after the use of checkpoint inhibitors relevant for intensive care medicine. RESULTS: Immune-related adverse events during therapy with checkpoint inhibitors are difficult to diagnose and present with various symptoms. Severe complications can often successfully be treated with early therapy. CONCLUSIONS: The early treatment of immune-related adverse events according to their severity is needed to prevent a potentially life-threatening course.